Compounder Draws Warning Letter for Misbranded, Unapproved Drugs By Sam | February 12, 2017 The FDA Philadelphia district office has issued a warning letter to a compounding pharmacy in Allentown, PA over misbranded drugs and sterility issues. Source: Drug GMP Report Posted in Drug GMP Report